Amneal Pharmaceuticals to Acquire Enzon Pharmaceuticals
Ticker: ENZN · Form: 8-K · Filed: Dec 27, 2024 · CIK: 727510
Sentiment: neutral
Topics: acquisition, merger, pharmaceuticals
TL;DR
Amneal buying Enzon, deal expected Q1 2025.
AI Summary
Enzon Pharmaceuticals, Inc. announced on December 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuticals LLC. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This acquisition will expand Amneal's specialty pharmaceutical business.
Why It Matters
This acquisition signifies a consolidation within the pharmaceutical sector, potentially impacting drug development pipelines and market competition.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until completion.
Key Players & Entities
- Enzon Pharmaceuticals, Inc. (company) — Company being acquired
- Amneal Pharmaceuticals LLC (company) — Acquiring company
- December 18, 2024 (date) — Date of definitive agreement
- first quarter of 2025 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Enzon Pharmaceuticals, Inc. has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuticals LLC.
Who is acquiring Enzon Pharmaceuticals?
A subsidiary of Amneal Pharmaceuticals LLC is acquiring Enzon Pharmaceuticals.
When was the definitive agreement for the acquisition signed?
The definitive agreement was signed on December 18, 2024.
When is the acquisition expected to be completed?
The acquisition is expected to close in the first quarter of 2025.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2024-12-27 16:30:45
Key Financial Figures
- $1,274,400 — erred Stock") in an aggregate amount of $1,274,400, or $31.86 per share of Series C Prefer
- $31.86 — n an aggregate amount of $1,274,400, or $31.86 per share of Series C Preferred Stock.
Filing Documents
- tm2432135d1_8k.htm (8-K) — 22KB
- 0001104659-24-132163.txt ( ) — 184KB
- enzn-20241218.xsd (EX-101.SCH) — 3KB
- enzn-20241218_lab.xml (EX-101.LAB) — 33KB
- enzn-20241218_pre.xml (EX-101.PRE) — 22KB
- tm2432135d1_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: December 27, 2024 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary